Trial Profile

A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaximin (Primary)
Indications Irritable bowel syndrome
Focus Registrational; Therapeutic Use
Acronyms TARGET-3; Trial 3
Sponsors Bausch Health Companies; Salix Pharmaceuticals; Valeant Pharmaceuticals International

23 May 2021 Results (n=3837) of pooled post hoc analysis of assessing efficacy of 3 Phase III studies TARGET-1, TARGET-2 and TARGET-3, presented at the Digestive Disease Week 2021.
17 May 2021 According to a Salix Pharma media release, results of pooled post hoc analysis will be presented at Digestive Disease Week (DDW) 2021.
13 Oct 2020 Results of post hoc analysis assessing the subgroup of patients with a history of IBS medication use before the study presented at the 28th United European Gastroenterology Week

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com